Work

Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

Year: 2001

Type: article

Study design: Clinical Trial

Source: PubMed

Authors: C M Rudin, J Holmlund, G F Fleming, S Mani, W M Stadler, P Schumm, B P Monia, J F Johnston, R Geary, R Z Yu, T J Kwoh, F A Dorr, M J Ratain

Institutions: University of Chicago Medical Center, University of Chicago

Language: English

Topic: RNA Interference and Gene Delivery

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

Award: GENETIC AND GENOMIC RESPONSES TO DNA DAMAGE

OpenAlex ID: W2099515475

FWCI: 4.668

Cites: 27

Cited by: 114

Related to: 10